eIF3c: a potential therapeutic target for cancer

Rafi Emmanuel1, Shiri Weinstein, Dalit Landesman-Milo

  • 1Laboratory of Nanomedicine, Department of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel.

Cancer Letters
|April 30, 2013
PubMed

Insights

Targeting the housekeeping gene eIF3c, vital for protein synthesis, shows therapeutic potential against diverse cancers. RNA interference (RNAi) against eIF3c effectively reduced cancer cell proliferation and induced cell death, highlighting its broad applicability.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Nanomedicine

Background:

  • Cancer cells exhibit genomic instability, leading to heterogeneity and therapeutic challenges.
  • Targeting ubiquitously expressed housekeeping genes offers a potential strategy against diverse malignancies.

Purpose of the Study:

  • To investigate the therapeutic potential of the housekeeping gene eIF3c in various cancer cell lines.
  • To evaluate the efficacy of targeting eIF3c using RNA interference (RNAi) approaches.

Main Methods:

  • RNAi-mediated downregulation of eIF3c in five cancer cell lines (NCI-ADR/RES, HeLa, MCF7, HCT116, B16F10).
  • Assessment of global protein synthesis, cell cycle arrest, proliferation, and cell death.
  • Utilized hyaluronan (HA)-coated lipid-based nanoparticles (LNPs) for siRNA delivery in mouse melanoma cells.

Main Results:

  • eIF3c downregulation significantly decreased global protein synthesis and induced polysome run-off.
  • Reduced eIF3c expression led to cell cycle arrest (G0/G1 or G2/M) in a tissue-dependent manner.
  • This resulted in decreased cell proliferation and induced cancer cell death, with successful siRNA delivery via HA-coated LNPs.

Conclusions:

  • The housekeeping gene eIF3c is crucial for translation initiation and cancer cell survival.
  • Targeting eIF3c presents a promising therapeutic strategy for heterogeneous malignancies.
  • Ubiquitously expressed genes like eIF3c are more effective targets than tumor-specific overexpressed genes.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...